Current Report Filing (8-k)
November 10 2022 - 5:19PM
Edgar (US Regulatory)
0001850119
false
0001850119
2022-11-10
2022-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 10, 2022
Century Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40498 |
|
84-2040295 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
3675 Market Street
Philadelphia, Pennsylvania |
|
19104 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (267) 817-5790
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name
of Exchange on Which
Registered |
Common Stock, par value $0.0001 per share |
|
IPSC |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 7.01 |
Regulation FD Disclosure |
On November 10, 2022, Century Therapeutics, Inc.
(the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation
in various meetings with investors from time to time.
The information contained in this Item 7.01
(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange
Act, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed
to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
The following exhibit is being furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CENTURY THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/ Osvaldo Flores, Ph.D. |
|
Name: |
Osvaldo Flores, Ph.D. |
|
Title: |
President and Chief Executive Officer |
Date: November 10, 2022
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Sep 2023 to Sep 2024